to France and Italy, the acquired EPD Business has further grown the company’s presence in various European markets, including the U.K., Spain, and markets in Eastern Europe. Rest of World The company markets generic pharmaceuticals in Rest of World through its subsidiaries in India, Australia, Japan, New Zealand and Brazil. Additionally, the company has an export business, which is focused on countries in Africa and emerging markets throughout the world; and through the company’s subsidiary, Mylan Laboratories Limited (Mylan India), the company markets API to third parties and also supplies the company’s other subsidiaries. Mylan India markets API to third parties worldwide and antiretroviral therapy products for people living with HIV/AIDS. In addition, Mylan India has an improving commercial presence, the company’s franchises include Critical Care, Hepato Care, HIV Care, Onco Care, and Women’s Care. The company has expanded its products from therapeutic categories, such as oncology and critical care. In November 2015, the company completed its acquisition of Jai Pharma Limited, which expanded the company’s women’s care portfolio and strengthened its technical capabilities in terms of hormone manufacturing. In 2013, the company established an exclusive long-term strategic collaboration with Pfizer Japan Inc. to develop, manufacture, distribute, and market generic drugs in Japan. In addition to the company’s operations in India, Australia and Japan, it has a notable presence in New Zealand and an improving presence in Brazil. Specialty segment This segment’s specialty pharmaceutical business is conducted through Mylan Specialty L.P. (Mylan Specialty). Mylan Specialty’s portfolio consists primarily of branded specialty injectable and nebulized products. A major portion of Mylan Specialty’s revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that is sold in the U.S. and internationally. Mylan Specialty has worldwide rights to the epinephrine auto-injector, which is supplied to Mylan Specialty by a wholly owned subsidiary of Pfizer Inc. Anaphylaxis is a severe allergic reaction that is rapid in onset and might cause death, either through swelling that shuts off airways or through a significant drop in blood pressure. Perforomist Inhalation Solution is a Mylan Specialty’s Formoterol Fumarate Inhalation Solution. Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for long-term, twice-daily administration in the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients, including those with chronic bronchitis and emphysema. Mylan Specialty holds various U.S. and international patents protecting Perforomist Inhalation Solution. In addition to EpiPen Auto-Injector and Perforomist Inhalation Solution, Mylan Specialty also markets ULTIVA, which is an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures and is generally administered by an infusion device. Customers and Marketing Generics: In North America, the company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, and mail order pharmacies. The company also markets its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies, GPOs, and government entities. These customers, called ‘indirect customers’, purchase the company’s products primarily through its wholesale customers. In Europe and Rest of World, generic pharmaceuticals are sold to wholesalers, independent pharmacies, and in certain countries, directly to hospitals. The company’s API is sold primarily to generic finished dosage form manufacturers throughout the world, as well as to the company’s other subsidiaries. Specialty: Mylan Specialty markets its products to different customer audiences in the U.S., including healthcare practitioners, wholesalers, pharmacists and ph
mylan nv (MYL:NASDAQ GS)
Hertfordshire, AL10 9UL
Phone: 44 1707 853000
Fax: 44 1707 261803www.mylan.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for MYL.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact MYLAN NV, please visit www.mylan.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.